What Bell Pharmaceuticals & Cosmetics does

Bell Pharmaceuticals & Cosmetics Private Limited is an Indian privately-held contract development and manufacturing organization (CDMO) headquartered in Siddipet, Telangana, operating 15 advanced manufacturing facilities that produce pharmaceutical formulations, nutraceuticals, cosmetics, and dermatology products on behalf of Indian and multinational clients. The company was established in 2010 as Bell Pharmaceuticals Ltd, expanded into pharmaceutical manufacturing with Plant 1 in 2015, and now claims to contribute roughly 9–10% of India's total medicinal requirements while serving 500+ clients globally including named enterprise customers such as Abbott. Its technology stack includes Novel Drug Delivery Systems (N.D.D.S), differentiated dosage formats (gummies, mouth-melt tablets, effervescent sachets), a centralized stability center following ICH guidelines, and the ARKA 24,000 sq ft NABL-accredited analytical laboratory in Hyderabad for chemical, microbiological, and stability testing.

The company's revenue model is built on B2B contract manufacturing services — including Contract Research and Manufacturing Services (CRAMS), technology transfer, loan licensing, contract development, and technical collaborations — priced on a custom quote basis per client requirement, formulation complexity, and volume, typically structured as multi-year contracts. Customer segments span pharmaceutical companies (primary), nutraceutical companies, and cosmetics and dermatology brands, served through direct enterprise sales and export channels across India, Brazil, Nigeria, Ghana, and Malawi. Certifications are a core commercial asset: WHO-GMP, State GMP, ISO 9001:2008, ISO 14001:2004, DSIR-approved R&D, US-NSF (nutraceuticals), NABL (testing), DCGI and FSSAI approvals, with ANVISA, NAFDAC, FDB, PMPB, EU GMP, and PIC/S GMP actively in progress. Leadership is founder-controlled, with Y Madhusudhan Reddy as Chairman & MD, Dr K Someshwar as Director & CEO, and Satwik Reddy Legala as a recent investor. The company operates two wholly-owned subsidiaries: Bell Nutravedics Ltd (nutraceuticals, US-NSF approved) and ARKA Pharmaceutical Testing Labs (NABL accredited).

Name

Bell Pharmaceuticals & Cosmetics

Legal name

Bell Pharmaceuticals & Cosmetics Private Limited

Website

https://bellpharmagroup.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

51–100 employees

Short description

Bell Pharmaceuticals & Cosmetics is an Indian CDMO operating 15 manufacturing facilities that produce pharmaceuticals, nutraceuticals, cosmetics, and dermatology products on a contract manufacturing basis for 500+ Indian and multinational pharmaceutical clients.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing & CDMO Services

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

akta.pro secondary industries

Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Pharmaceutical contract manufacturing
• Nutraceutical manufacturing services
• Cosmetics contract manufacturing
• Dermatology product manufacturing
• CRAMS services

Headquarters

HQ city

Siddipet

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Others

Revenue model

1. Contract Manufacturing Services (CRAMS): Contract Research and Manufacturing Services providing end-to-end services for drug development, manufacturing, and supply chain management. Services include Technology Transfer, Loan License, Contract Development, Novel Drug Delivery Systems, and Technical Collaboration/Joint Ventures.
2. Pharmaceutical Formulations: Manufacturing and supplying pharmaceutical formulations in various dosage forms including tablets, capsules, syrups, ointments under customer brand names
3. Nutraceutical Products: Production of dietary supplements, herbal/ayurvedic formulations, veterinary feed supplements for various market segments
4. Cosmetics & Dermatology Products: Manufacturing of cosmetic and dermatological products including hair care, personal care, and skincare products with cruelty-free testing methods

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Bell Pharmaceuticals & Cosmetics operates as a Contract Development and Manufacturing Organization (CDMO) producing pharmaceutical formulations (tablets, hard/soft gelatin capsules, syrups, ointments, sachets), nutraceutical and Ayurvedic formulations, veterinary feed supplements, and cosmetics/dermatology products across 15 advanced manufacturing facilities. It also provides end-to-end Contract Research and Manufacturing Services (CRAMS) including technology transfer, loan licensing, contract development, Novel Drug Delivery Systems (N.D.D.S), technical collaborations, and NABL-accredited analytical testing through its ARKA laboratory.

Product overview

Bell Pharmaceuticals & Cosmetics is a contract development and manufacturing organization (CDMO) offering integrated pharmaceutical, nutraceutical, and cosmetics manufacturing services. The portfolio includes core manufacturing of pharmaceuticals (tablets, capsules, syrups, ointments), nutraceuticals (supplements in various dosage forms including gummies and effervescent tablets), and cosmetics/dermatology products across multiple branded ranges. Services include Contract Research & Manufacturing Services (CRAMS), Novel Drug Delivery Systems (N.D.D.S), and NABL-accredited testing laboratory services under the ARKA brand. The company operates 15 advanced manufacturing facilities with capabilities spanning pharmaceuticals, nutraceuticals, cosmetics, and dermatology, supported by DSIR-approved R&D facilities.

Differentiator

Problem solved

Functional benefit

Brands

• Bell Nutravedics Ltd: Subsidiary entity specializing in nutraceuticals, food supplements, herbal and ayurvedic formulations, and veterinary feed supplements with US-NSF approved facility.

Quantifiable outcome

• 9-10% of India's total medicinal requirements met by Bell
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Multinational Pharmaceutical CompaniescoreOthersBell enables production for big multinationals and large pharmaceutical companies. The partnership involves providing end-to-end contract manufacturing services including drug development, technology transfer, and regulatory compliance support. Bell develops innovative, technology-driven products and manufactures them under customer brand names.

Scale indicators6 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Divi's Laboratories: India-headquartered global CDMO providing API and intermediate manufacturing services with significant scale in contract development and manufacturing for global pharma — directly comparable to Bell's CDMO positioning but operating at much larger scale and primarily in drug substance/API rather than finished dosage forms.
• Aurobindo Pharma: Large Indian pharmaceutical company with vertically integrated API and finished dosage manufacturing and an expanding third-party contract manufacturing franchise — broader than Bell but overlapping in generic formulation contract manufacturing.

Direct peers

• Piramal Pharma Solutions: India and global CDMO offering integrated contract development and manufacturing services across drug substance and drug product, including sterile fill-finish — a direct peer to Bell's end-to-end contract manufacturing model, serving multinational pharma clients with multi-site capacity.
• Jubilant Pharmova: Indian CDMO with contract manufacturing of sterile injectables, APIs, and radiopharma, serving global regulated markets; comparable to Bell in B2B pharma manufacturing and regulatory-driven export work.
• Suven Pharmaceuticals: India-based CDMO specializing in complex API and intermediate development and manufacturing for global pharma — comparable to Bell as an Indian CRAMS/CDMO serving multinational pharma clients.
• Neuland Laboratories: Indian CDMO providing API contract manufacturing, custom synthesis, and formulation services to global pharma — directly comparable to Bell's business model of contract manufacturing for innovator and generic drug companies.
• MSN Laboratories: Indian pharmaceutical manufacturer with active contract manufacturing services across APIs and formulations including FDCs and novel drug delivery systems — directly comparable to Bell's FDC and N.D.D.S positioning and Indian-multinational customer mix.
• Aizant Drug Research: India-based CRO/CDMO offering formulation development, analytical services, and commercial contract manufacturing for global pharma — closely comparable to Bell on CDMO services, formulation R&D, and analytical testing capabilities.

Others

• Syngene International: India's largest listed CRO/CDMO providing contract research, development, and manufacturing services for global pharma and biotech — comparable to Bell's CRAMS offering with a stronger discovery/research tilt but similar international pharmaceutical customer base.

Regional players

• Arbro Pharmaceuticals: Indian pharmaceutical manufacturer and contract manufacturer with formulation production across dosage forms, plus an in-house analytical testing vertical — comparable to Bell as an Indian multi-vertical private CDMO with limited international footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/Bell-Pharmaceuticals-and-Cosmetics-Pvt-Ltd-61552417524825
• LinkedInlinkedin.com/company/bell-pharmaceuticals-and-cosmetics-private-limited

Compliance18 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bell Pharmaceuticals & Cosmetics